Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting Non-phase study NCT07498829

Population Based Germline Testing for Early Detection and Prevention of Cancer

Population Based Germline Testing for Early Detection and Prevention of Cancer — Recruiting • Non-phase study • Oncology • NCT07498829.

📅 27 Mar 2026 ⏱ 4 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT07498829
Sponsor
Queen Mary University of London
Start
2025-12-18
ClinicaliQ Trial Snapshot
  • Population Based Germline Testing for Early Detection and Prevention of Cancer — Recruiting • Non-phase study • Oncology • NCT07498829.
  • PROTECT-C is a research study offering genetic testing to people to see whether they have a genetic change that increases their risk of breast, ovary, bowel, and/or womb cancer. This is regardless of whether they or their families have had cancer. Breast,….
  • Sponsor: Queen Mary University of London.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

PROTECT-C is a research study offering genetic testing to people to see whether they have a genetic change that increases their risk of breast, ovary, bowel, and/or womb cancer. This is regardless of whether they or their families have had cancer. Breast, ovary, bowel, and womb cancers make up half of all cancers in women. Around 15-20% (15 to 20 in 100 cases) of ovary and 3-4% (3 to 4 in 100 cases) of breast, womb, and bowel cancers are linked to cancer genes and may be prevented. People with…

Eligibility Snapshot
  • : * Women, trans men, and non-binary people with female reproductive organs * ≥18 years at consent

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Early Breast Cancer: Diagnosis and Management (NICE NG101)
Oncology · 25 Mar 2026
Perform triple assessment (clinical examination, imaging, and biopsy) for all suspicious breast lesions to confirm diagnosis before treatment planning Offer breast-conserving surgery…
View guideline →
Guideline
Ovarian Cancer: Recognition and Initial Management (NICE NG241)
Oncology · 27 Mar 2026
Perform CA125 blood test and pelvic ultrasound (including ovarian assessment) as first-line investigations in primary care when ovarian cancer is suspected based…
View guideline →
Guideline
Colorectal Cancer: Diagnosis and Management (NICE NG151)
Oncology · 27 Mar 2026
Refer adults with rectal bleeding plus abdominal pain, change in bowel habit, weight loss, iron-deficiency anaemia, or age >60 with unexplained symptoms…
View guideline →
Clinical Brief
Women attending first NHS mammogram hits 10-year high as thousands more cancers found
Oncology · NHS England · 19 Feb 2026
Hundreds of thousands more women attended NHS breast screening last year and thousands more cancers were diagnosed early in England. New figures…
View brief →
Clinical Brief
11 cancers on the rise in young people – scientists find first clue why it’s happening
Oncology · BBC Health · 28 Apr 2026
Early-onset cancers are increasing across 11 cancer types in younger populations, representing a clinically significant epidemiological shift requiring increased diagnostic vigilance Scientists…
View brief →
Guideline
Head and Neck Cancers: Diagnosis and Management (NICE NG36)
Oncology · 27 Mar 2026
Refer urgently (two-week wait) any adult with unexplained persistent hoarseness, dysphagia, otalgia, oral ulceration lasting more than 3 weeks, or suspicious neck…
View guideline →